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Abstract
Many diseases that affect the gastrointestinal tract (GIT) have great influence on 
the quality of life of the majority of patients. Many probiotic strains are being highly 
studied as a promising candidate due to their beneficial effect reported in the GIT. With 
the purpose of increasing the beneficial characteristics of some probiotics strains 
and, consequently, to improve further the reported results, many probiotic strains 
expressing or encoding different proteins, with anti-inflammatory activities, have been 
developed. These recombinant strains have been reported as good candidates for the 
treatment of different pathological conditions, especially colitis and mucositis disease 
since they have been shown to have positive results and good perspectives for GIT 
inflammation. Thus, this chapter will first address the aspects of the gastrointestinal 
tract in humans as well as its microbiota. In a second moment, it will discuss about 
chronic diseases, mainly the intestinal ones. Finally, it will discuss about probiotics, 
especially concerning on lactic acid bacteria (LAB), and its action in the prevention and 
treatment of these diseases. At the final part, we will point out aspects on the develop-
ment of recombinant strains and the results found in the literature on disease models.
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1. The human gastrointestinal tract
The human gastrointestinal tract is formed by a complex ecosystem which 
includes the gastrointestinal epithelium, immune cells, and resident microbiota 
[1] and comprehends one of the biggest existent interfaces between the host, 
environmental factors, and antigens in the human body.
The intestine encompasses a broad variety of microorganisms (bacteria, archaea, 
eukarya, and viruses) [2] from more than 3500 different species [3, 4] that coevolved 
with the host in a mutually beneficial relationship [5, 6]. The composition and density 
of bacterial populations in adult individuals differ considerably over the GIT. The area 
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of the GIT that has highest microorganism abundance is the colon (1014) followed 
by dental plaque (1012), ileum (1011), saliva (1011), and skin (1011) [7]. However, low 
concentrations (up to 102–107 cells/mL) and bacterial diversity are found in the upper 
GIT (stomach, duodenum, jejunum) [3, 4], since the presence of acid, bile salts, and 
pancreatic secretions hinders the bacterial colonization [8], so that there is no nutri-
tional competition between the microbiota and the host [9]. Thus, both function and 
structure of microbial communities are significant and are closely related. However, 
function could be the more important measure of microbiome health, since bacterial 
ecology suggests that analogous ecosystems have similar function although they have 
moderately diverse composition [10, 11].
2. Gut microbiota
The importance and the specific functions that gut microbiota has in human 
nutrition and health are well settled. The attributed functions can be classified 
in three classes: metabolic, protective, and trophic [12]. The gene diversity of the 
microbial community provides a variety of enzymes and biochemical pathways, 
specific to the host, able to contribute to short-chain fatty acid (SCFA) production by 
carbohydrate fermentation and production of some vitamins such as K, B12, biotin, 
folic acid, and pantothenate. These factors added to synthesis of amino acids from 
ammonia or urea contributing to the metabolic function of the microbiota [13, 14].
The gut microbiota’s protective function is related to barrier effect, once the 
resident bacteria generate a resistance line which avoid pathogens/opportunistic 
bacteria and maintain normal mucosal function. The activity of some bacteria to 
secrete antimicrobial substances, such as bacteriocins, is able to inhibit the growth 
of other bacteria and nutrient competition [15, 16].
Regarding trophic functions of gut microbiota, the interaction between resident 
microorganisms has influence in differentiation and proliferation of epithelial cells 
[17], as well as in the development and regulation of the immune system by numerous 
and varied interactions between microbes, epithelium, and gut lymphoid tissues [18].
It is important to highlight that the interactions between the gut microbiota 
and the host immune system are required to preserve the gut homeostasis [19–21]. 
When this relationship is affected, alterations in bacterial function and diversity 
lead to the imbalance in the composition of the resident microbiota, favoring either 
the growing of pathogenic bacteria or the decreasing in beneficial bacteria in a 
process known as dysbiosis [22], which appoint a great threat to gut integrity and is 
intrinsically related to the development and progression of several diseases, such as 
inflammatory bowel diseases.
3. Chronic inflammatory diseases
One of the most well-characterized chronic inflammatory diseases that 
mainly affect the digestive tract is inflammatory bowel disease (IBD), which 
includes ulcerative colitis (UC) and Crohn’s disease (CD). The exact etiology of 
IBD is still unclear, but the strict relation between genetic and the environmental 
factors, such as enteric immune dysregulation and alterations in the intestinal 
microbiome [23, 24], is broadly known. Besides, these diseases generate sub-
stantial morbidity and have a high prevalence in developed countries (5 in 1000 
individual are affected) they remain to increase in developing nations [25].
Both diseases, UC and CD, present different pathogenesis, symptomatology, inflam-
matory profiles, and gut microbiota composition. CD is characterized by the irregular 
transmural inflammation (extending deeply into the submucosal regions) which can 
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affect any portion of the GIT and often made difficult by strictures, abscesses, and 
fistulae. On the other hand, the inflammation presented in UC is restricted to the 
superficial layers of the intestinal mucosa characterized by mucosa erosion and/or 
ulcer, generally localized in the region of the gut most colonized by bacteria, the colon 
[26, 27]. In addition, regarding the immune response associated with these diseases, it 
is possible to relate CD with an increased IL-12, IL-23, IL-27, interferon γ (IFN-γ), and 
tumor necrosis factor-α (TNF-α) production, all associated with Th1 and Th17 immune 
responses, different from UC which is correlated with a Th2 immune response, with 
high levels of IL-5 and transforming growth factor-β (TGF-β) production [28].
4. IBD complications and microbiota manipulation
It is important to highlight that the principal cause of death in IBD patients is 
colorectal cancer (CRC) [29]. Frequent episodes of inflammatory process in the 
intestinal mucosa are related to development of this disease, which is the second 
most frequently identified cancer in females and the third in males.
There are increased evidences that environmental factors such as lifestyle and 
diet alterations have effect in CRC incidence [30]. This effect has been documented 
because there is evidence showing an essential relationship between dietary 
antigens and antigens of commensal bacteria with the regulatory T cells (Tregs), 
which maintain the immune tolerance and, consequently, reduce the risk of 
tumorigenesis associated with inflammation [31].
In this context, it was reported that the higher consumption of diet rich in 
grains and vegetables decreases the incidence of CRC. This effect involves different 
mechanisms such as the diminution in the fecal transit time due to the increase in 
the stool bulk, and consequently, it reduces the contact of carcinogen with colon 
cells and the fermentation of these fibers of colonic components [14, 32]. In addi-
tion, significant reduction in concentration of acetate, propionate, and butyrate 
with increase in fecal pH [33] and the decrease in the number of obligate anaerobe 
microorganisms have been reported in individuals with colon cancer [34] when 
compared with healthy people. Thus, intestinal environmental alterations are the 
keys to evolution toward adenoma and afterward to CRC progression [35].
It has been also reported that up to 30% of patients with UC need surgical man-
agement such as the restorative proctocolectomy with ileal pouch-anal anastomosis 
(IPAA) [36]. This procedure removes the entire colon and rectum while preserving 
the anal sphincter and, hence, normal bowel function and fecal continence, therefore 
acting as an internal pelvic place for intestinal contents [37]. Around 50–60% of UC 
patients with following IPAA develop inflammation in the ileal pouch, generating the 
condition called “pouchitis.” The reported incidence of pouchitis is variable, generally 
because of the diagnostic criteria that have been used to define this syndrome [38, 39]. 
In addition, although its pathogenesis is uncertain, the main hypothesis for the mecha-
nism by which the disease occurs is the break in the mucosal barrier generated by 
dysbiotic microbiome in susceptible patients, generating an unusual mucosal immune 
activation [40]; still the disease typically responds to antibiotics.
Corresponding to the increased attention given to the role of the intestinal 
microbiota in a variety of diseases, there has been an intense exploration of poten-
tial means to manipulate the intestinal microbiome either by probiotic administra-
tion or fecal microbiota transplant (FMT) for therapeutic effect [41].
In this context, a randomized clinical trial based on a 1-week treatment with 
anaerobically prepared donor FMT, compared with autologous FMT, resulted in a 
higher probability of remission in 8 weeks for patients with UC, revealing that stool 
administration from healthy donors to UC or CD patients is an intervention that seeks 
to restore a healthier balance of gut microbes and control IBD [42]. Data on FMT for 
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Crohn’s disease is rather more limited than for UC, but it has been shown that single 
standardized FMT resulted in a clinical remission sustained for more than 9 months 
in CD patients [43]. However, the authors suggest that further studies are needed to 
enhance the knowledge about the use of stool transplantation for IBD treatment.
Alteration in the gut microbiome composition with increase in some groups 
of microorganisms, such as Clostridium and Fusobacterium, was also reported in 
patients with pouchitis [44, 45]. In this context, literature evidences indicate that 
the probiotic administration such as VSL#3 is effective in the chronic pouchitis 
prevention [46]. On the other hand, FMT to pouchitis treatment did not report the 
same beneficial results. Only three reports with this approach [47–49] exposed that 
neither clinical remission nor any adequate response was observed in the evaluated 
patients suggesting that the efficacy of FMT for pouchitis after proctocolectomy 
is limited [49]. The importance of standardization of this procedure needs to be 
highlighted to improve its efficacy, since frequency, route of administration (e.g., 
endoscopy, nasogastric tube, colonoscopy), and the criteria of choice of healthy 
donor are very important parameters to be considered.
5. Intestinal mucositis
Different chemotherapy regimens such as FOLFOX (5-fluorouracil and 
oxaliplatin), FOLFIRI (5-fluorouracil and irinotecan), and triple FOLFOXIRI 
regimen (5-fluorouracil, oxaliplatin, and irinotecan) [50, 51] are adopted for 
different types of cancer but with a broad range of collateral effects.
Mucositis is the most common side effect in patients undergoing chemotherapy/
radiotherapy treatments, which consist in an inflammation and/or ulcers in the 
gastrointestinal tract [52] with consequent loss of cells from the epithelial barrier of 
the GIT. Many symptoms are related to gastrointestinal mucositis, such as diarrhea, 
severe abdominal pain, bleeding, fatigue, malnutrition, dehydration, electrolyte 
imbalance, and infections, with potential fatal complications which can conduce 
to reduction or interruption of antitumor treatment [53] and consequently leads to 
longer hospitalization.
This pathology occurs due to cytotoxic effects of anticancer drugs/radiotherapy 
that cause damage at the DNA of stem cell (epithelial cell progenitors) with intense 
oxidative stress and consequent cell death. This apoptotic process is exacerbated 
affecting the absorption by shortening the villi structure of enterocytes and causing 
the loss of epithelial barrier with an invasion of inflammatory cells (neutrophils, 
eosinophils, and macrophages) leading to an increased production of inflammatory 
mediators at the mucosal area with consequent epithelial erosion and ulceration. The 
progressive destruction of mucosal integrity causes the rupture of the tight junc-
tions proteins, leading to an increase in the intestinal permeability with subsequent 
penetration of commensal microbiota to the submucosal layer generating bacteria 
translocation which exacerbates the inflammatory process and intensifies the symp-
toms [53–57]. Besides, the intestinal microbiota composition is also modified by the 
chemotherapeutic drugs and radiotherapy action [54, 58, 59] resulting in dysbiosis. 
After the end of treatment, recovery and restoration of the GIT structure occur [60].
6. Metabolic syndrome
Besides IBD and mucositis, it has been reported that intestinal microbiota has 
an intrinsic effect on metabolism, potentially contributing to several features of 
the pathophysiology of metabolic syndrome [61, 62]. The metabolic syndrome is 
an accumulation of various risk factors (glucose intolerance, hyperinsulinemia, 
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hypertension, as well as dyslipidemia) which can often be associated with insulin 
resistance, hypertension with abdominal fat accumulation, and obesity [63–65].
The etiology of metabolic syndrome is not well-defined; however there are 
evident characteristics and life habits that could contribute to its development 
such as unbalanced diet, smoking, lack of physical activity, and the genetic 
predisposition [66]. These factors directly increase the risk of cardiovascular 
disease and chronic diseases as type 2 diabetes mellitus and obesity, and the 
interaction between components of both the clinical and biological phenotypes of 
the syndrome contributes to the development of a pro-inflammatory state [67].
The inflammatory process observed in MS is directly associated with increased 
oxidative stress. The reactive oxygen species (ROS) are capable of mediating 
symptoms of diabetes mellitus, such as insulin resistance and decrease in insulin 
secretion, and attend as precursors for the formation of LDLox (oxidized low-
density lipoproteins), responsible for a large part of the development of atheroscle-
rotic lesions, and the increase in circulating cholesterol fractions and glucose [68, 
69]. In addition, chronic diseases are directly related to changes in the intestinal 
microbiome [70, 71], and they are also associated with elevated circulating levels of 
pro-inflammatory cytokines such as TNF and IL-6 [72].
The probiotic use in attenuating symptoms of different inflammatory dis-
eases is widely reported in the literature. Among the commercial probiotics 
studied for treatment of these diseases, only a few products have been exten-
sively tested in clinical trials in patients with MS, in order to demonstrate an 
effective result on weight loss, lipid metabolism, and reduction of inflammatory 
markers.
Studies performed with Lactobacillus strains have shown the ability of these 
probiotics in reducing the lipid accumulation in adipose tissues, as well as in induc-
ing the subexpression of lipogenic genes [73, 74]. Animals that received diets with 
high concentrations of lipids and then treated with L. gasseri SBT2050 had shown 
lower intestinal permeability and bacterial translocation, as well as reduction of 
inflammatory parameters, suggesting that this strain improves the intestinal barrier 
function [75–78]. In addition, L gasseri BRN17 was studied to treat animals with 
MS caused by the carbohydrate-rich diet consumption. This strain reduced the 
accumulation of adipose tissue in mice, and it has a beneficial effect on weight loss 
[79–81]. Another important approach with associated probiotics (Bifidobacterium, 
Lactobacillus, and S. thermophilus) for treatment of overweight patients has shown 
an improvement in lipid profile, as well as insulin sensitivity [82]. Besides, recently 
Hsieh e collaborators [83] demonstrated that administration of live Lactobacillus 
reuteri ADR-1 and killed Lactobacillus reuteri ADR-3 strain ameliorated type 2 
diabetes mellitus in a clinical trial. The results indicated that the consumption 
of ADR-1 displayed a reduction effect on serum glycated hemoglobin (HbA1c), 
triglyceride, and cholesterol levels. On the other hand, the intake of ADR-3 showed 
a beneficial effect on blood pressure reduction. Besides, a reduction in the levels 
of pro-inflammatory cytokines (IL-1β), increase in antioxidant enzyme (super-
oxide dismutase), and the changes in intestinal microflora composition (increase 
in intestinal level of Lactobacillus spp. and Bifidobacterium spp. and decrease in 
Bacteroidetes) were observed. Thus, these strategies highlight the beneficial and 
potential effect of interventions targeting gut microbiota modulation by the use of 
probiotic strains to treat components or complications of metabolic syndrome.
7. Functional foods
The human being for more than 4000 years has been consuming fermented 
products, by the fermentation process. At the beginning this practice was done 
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to preserve foods from either physical, chemical, or microbial alterations. The 
microorganisms participating in this process are the lactic acid bacteria, extensively 
widespread in nature and also belong to the GIT communities, able to convert the 
sugar in lactic acid as well as produce other metabolites which contribute to food 
modifications, either sensorial or nutritional value. Thus, the terminology “func-
tional food” was attributed to food with health benefits to the consumer including 
nutritional and physiological function [84–86].
During the fermentation, these bacteria can contribute to improving the digestion 
of nutrients (lactose, proteins, small peptides, and polysaccharides); providing essen-
tial micronutrients (vitamins) as well as bioactive compounds (metabolites) with 
potential health benefits to the host, such as prevention against enteric inflammation 
[87, 88]; providing antimicrobial, antihypertensive, hypocholesterolemic, immuno-
modulatory, antioxidant, and anticancer effects [46, 85, 89–92]; showing ability to 
regulate the immunity; and, consequently, improving host quality of life [93].
Therefore, the gut communities and the microbial-derived molecules present in 
the gut lumen have been strongly influenced, either qualitatively or quantitatively, 
by consumption of dairy products [94] such as yogurts, cheeses, and fermented 
milk, among other fermented products using probiotic bacteria. Thus, the micro-
biota manipulation by functional food, probiotics, and prebiotics are evaluated as a 
beneficial option for treatment of GIT diseases [95].
8. Lactic acid bacteria: the largest group of probiotic bacteria
There is a constant interaction between the host and the bowel commensal 
bacterial community in order to maintain the homeostasis [3, 96–98]. However, 
when this mutualist relationship is compromised, the intestinal microbiota 
may cause and/or contribute to either the establishment or the progression of 
inflammatory diseases [96–99]. In this context, the search for therapeutic strategies 
that minimize the development and progression of pathologies caused directly 
and indirectly by the unbalance of the commensal microbiota has grown. The 
consumption of probiotic bacteria is one of these strategies, as they present several 
effects, such as ability to improve the intestinal barrier, stimulate the systemic and 
mucosal immune system, regulate the composition of the intestinal microbiota, and 
provide essential micronutrients (such as vitamins and SCFAs) and other bioactive 
compounds (metabolites) with potential health benefits for the host [100–103].
Probiotics are defined as “live microorganisms that offer host health benefits when 
administered in adequate amounts” [104, 105]. The majority of the studied probiot-
ics belongs to the group of lactic acid bacteria. However, other microorganisms with 
probiotic properties also deserve attention, such as yeasts (Saccharomyces spp.) and 
bacteria of the genus Bifidobacterium and Faecalibacterium, among others [106–108].
LAB, which include, mainly, species from the genus Lactobacillus, Leuconostoc, 
Lactococcus, Pediococcus, and Streptococcus, constitute a group of Gram-positive, 
anaerobic or aerotolerant, nonspore-forming, nonmobile, and highly low pH-tolerant 
microorganisms. However, the main characteristic of this group is its ability to pro-
duce lactic acid as the final product of the fermentation of carbohydrates [109–111].
9. Probiotic effects in gastrointestinal inflammation
LAB are often present in the human gut but also can be introduced by the 
ingestion of fermented foods, such as yogurt and other fermented milk products 
and fermented cured meat by-products [103], having the generally recognized as 
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safe (GRAS) status by the Food and Drug Administration (FDA). Lactobacillus spp., 
Streptococcus spp., and Lactococcus spp. are the major LAB species with probiotic 
effects, and they have been used in therapeutic applications for treatment and 
prevention of various intestinal disorders [112, 113].
Scientific evidence reveals that the mechanisms by which probiotic bacteria 
ameliorate inflammatory bowel damage are heterogeneous, strain specific, and 
dependent on the number of available bacteria. Thus, administration of probi-
otic bacteria, specially LAB, improves intestinal inflammatory responses by (i) 
modulation and normalization of perturbed intestinal microbial communities; (ii) 
competitive exclusion of pathogens such as Staphylococcus aureus and Salmonella 
typhimurium, among others; (iii) bacteriocin and SCFA production; (iv) enzymatic 
activities related to metabolization of a number of carcinogens and other toxic 
substances; (v) adhesion to mucosal cells, cell antagonism, and mucin production; 
(vi) intestinal permeability reduction by tight junctions protein modulation (e.g., 
zonulin, claudin, occludin, junctional adhesion molecule); (vii) modulation of the 
immune system by stimulating Tregs cells, IgA production by B cells, and NF-kβ 
signaling pathway inhibition; and (viii) interaction with the brain-gut axis via the 
generation of bacterial metabolites (Figure 1) [103, 114–118].
10. Recombinant LAB probiotics
In order to potentialize the beneficial effects of probiotic strains, research has 
been conducted over the last decades, based on genetic engineering techniques, 
especially those related to DNA manipulation. Thus, modern methods of genetic 
engineering open the new opportunities to design and create genetically modified 
probiotic strains with the desired characteristics or to exclusively target a specific 
pathogen or toxin to be used either as a vaccine or for drug delivery [119, 120]. 
Since most of the probiotic strains are part of the LAB group, most of the genetic 
manipulation studies are carried out with species that belong to this group, such as 
Lactococcus and Lactobacillus genera. Consequently, recombinant probiotics have 
been created for mucosal delivery of therapeutic and/or prophylactic molecules 
comprising DNA, peptides, single-chain variable fragments, cytokines, enzymes, 
and allergens [121, 122], leading to the concept of “biodrug” for the prevention and 
treatment of various diseases [123]. Thus, researches have emphasized the use of 
species of these genera in two different approaches: the first as producers of heter-
ologous protein and the second as vehicle for delivery of DNA vaccines [124].
Figure 1. 
A schematic diagram about potential action mechanisms of probiotic bacteria.
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10.1 LAB as producers of heterologous protein
Many studies are carried out with Lactococcus lactis due to its economic 
importance in the production of cheese and its easy growth and manipulation. In 
addition, it was the first species of LAB to have its genome completely sequenced, 
which allowed a greater understanding of its genetic and physiological mechanisms, 
aiding in the development of technological packages for its genetic manipulation in 
a laboratory environment [124–128].
There are several ways to make LAB produce heterologous proteins, and the 
most used form is through the insertion of a plasmid into its cytoplasm. Plasmids 
are elements of extrachromosomal DNA that are naturally found in prokaryotes. 
With the advent of the recombinant DNA technique, these elements have been 
manipulated to act as molecular vehicles that allow the production of proteins of 
interest by the bacterium [129].
The first heterologous protein production system based on plasmid insertion 
in LAB was developed for L. lactis. These systems included both inducible and 
constitutive promoters, which ensure efficient expression of the antigen of inter-
est under different conditions [130, 131]. Although it is possible to choose the 
type of promoter to be used in the vector, the vast majority of expression vectors 
present inducible promoters that allow controlled expression of the protein of 
interest by protecting against aggregation and protein degradation in the bacte-
rial cytoplasm. On the other hand, these vectors present safety issues that need 
to be analyzed since it is necessary to introduce chemical compounds into the 
culture medium to induce protein expression prior to animal administration 
[132–134].
With the improvement of cloning and expression techniques, several production 
systems were developed, specifically for LAB, allowing the production of different 
molecules of interest, including pathogen antigens, by a large number of LAB species 
[135–139]. The most commonly used regulation systems in LAB are the following:
10.1.1 Nisin-controlled gene expression (NICE)
Among the heterologous production systems, the most widely studied is the 
nisin-controlled gene expression system. This system is based on the expression of 
three genes (nisA, nisF, and nisR) that are involved in the production and regula-
tion of the antimicrobial peptide nisin, which is naturally secreted by different 
strains of L. lactis. In this system the membrane-located histidine kinase NisK 
senses the signal inducer nisin and autophosphorylates and then transfers the 
phosphorous group to the intracellular response regulator protein NisR which acts 
as a transcription activator of nisA/nisF and induces gene expression under pNis 
promoter. Depending on the presence or absence of the corresponding targeting 
signals, the protein is either expressed into the cytoplasm or the cell envelope or 
secreted into the external medium [140]. Thus, it has already been successfully 
used for the expression of different proteins of medical and biotechnological 
interest [141, 142].
10.1.2 Xylose-inducible expression system (XIES)
In 2004, Miyoshi and colleagues [143] developed the xylose-inducible expres-
sion system whose promoter is the xylose permease gene (pxylT) found in L. 
lactis NCDO2118. This system produces either cytoplasmic or secreted proteins 
being activated in the presence of xylose and strongly repressed in the presence of 
glucose, fructose, or mannose [143].
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10.1.3 Stress-inducible controlled expression system (SICE)
More recently, the stress-inducible controlled expression system was developed 
using the L. lactis groESL promoter [134]. This system induces expression of 
proteins of interest via stress stimuli such as those found in the GIT (e.g., bile salt, 
acid pH, antimicrobial peptide, and heat shock proteins) [134, 144]. This system 
does not require the induction of bacterial culture or the presence of regulatory 
genes, being a good alternative in the delivery and production of therapeutic 
proteins at mucosal surfaces.
10.2 LAB as a live vehicle to deliver DNA vaccine plasmids to eukaryotic cells
Among the available approaches to stimulate efficient mucosal responses, the 
use of bacterial system for DNA delivery and its expression using the eukaryotic cell 
machinery have been extensively explored. Unlike the production of heterologous 
protein, in which the bacterium is responsible for the synthesis of the protein of 
interest, in the DNA vaccine platform, the bacteria only act as a delivery vehicle for 
prophylactic and therapeutic purposes [109, 145].
New vectors had been developed to approach the DNA vaccine using LAB as 
live delivery vehicles [146, 147, 148–150]. These vectors present a series of common 
characteristics such as the presence of a eukaryotic promoter, which allows protein 
expression by eukaryotic cells; a prokaryotic region, which has a selection marker 
(usually antibiotic resistance); a multiple cloning site, where the open reading 
frame (ORF) of interest will be inserted; and a prokaryotic origin of replication, 
which ensures that the plasmid replicates only in prokaryotic cells [151]. Some 
molecules (IL-10, IL-4, and HSP65) have been cloned in these vectors to evaluate 
their effect, especially as a treatment approach in diseases related to the bowel  
[152, 153], as well as reporters (GFP and Cherry) which allowed the understanding 
of this platform in the mammalian body [148, 154]. Although further studies need 
to be conducted in order to elucidate whether the cloning of ORFs of interest in 
these vectors is really effective pointing to disease prevention and treatment, this 
approach is undoubtedly an important tool for the development of new techniques 
with potential in the medical clinic.
11. Next-generation recombinants: using CRISPR-Cas system
Among the different techniques used to construct recombinant LAB strains, the 
most recent is associated with the use of the clustered regularly interspaced short 
palindromic repeats (CRISPR)-Cas system, based on the use of a system present 
in several bacterial strains that works as part of the adaptive immune system of 
bacteria and archaea against the presence of external DNA, such as plasmids and 
bacteriophages [155–159].
Although this system has been studied for more than 30 years [160], it was only 
in 2013 that the first experiments were carried out emphasizing its use as a tool 
for genome editing [161, 162]. Evaluating the CRISPR databases, it is possible to 
observe that about 46% of all bacterial genomes presents the CRISPR-Cas system, 
and this percentage reaches approximately 63% of the sequenced Lactobacillus 
genomes [163]. The natural presence of this system in most of the LAB strains 
expands the possibilities of genetic manipulation of microorganisms of this group, 
including probiotic ones [164].
The first gene editing experiment in LAB based on the CRISPR-Cas system was 
conducted by Oh and van Pijkeren [165] where they were able to edit three different 
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regions of the genome, with efficiency up to 100% in the selected clones. After this 
pioneering work, few others were published focusing on LAB gene editing [166–168].
Therefore, the use of this technology is presented as a widely viable strategy to 
be applied in LAB, enabling the development of food-grade recombinant strains in 
order to allow their future use in the clinic [169].
12. Use of recombinant LAB to treat GIT-related disorders
The use of recombinant L. lactis strains, as well as others recombinant LAB strains, 
using different systems has shown promising results in many studies as an alternative 
therapy to treat, especially, GIT inflammation and other diseases (Table 1).
To arrive at mucosa in sufficient quantities to exert their therapeutic effects, 
many LAB strains must survive, during their passage through the GIT, stressor 
factors such as pH, temperature, bile salt concentration, and the presence of 
antimicrobial peptides [170–172]. In this context, an interest approach was recently 
developed by Coelho-Rocha and colleagues [154] using an encapsulated recombi-
nant strain (L. lactis pExu:mcherry) and tested it through the GIT at different times 
post-administration. They have shown that the microencapsulation process is an 
effective method to improve DNA delivery, guaranteeing a greater number of viable 
bacteria able to reach different sections of the bowel [154].
The use of recombinant probiotics to improve therapeutic approaches has been 
widely studied using different systems with different molecules. As IBDs are a 
serious clinical topic, many strategies have been tested trying to improve previous 
results found with wild type strains.
L. lactis MG1363 strain carrying the pTREX1 vector expressing the mouse IL-27 
protected mice against the inflammatory effects of dextran sulfate sodium (DSS)-
induced colitis. This recombinant strain was able to reduce disease activity scores 
and pathology features of the large and small bowels and also led to reduced levels 
of inflammatory cytokines IL-1β, TNF-α, and IFN-γ in colonic tissue. In addition, 
reduction in the number of CD4+ and IL-17+ T cells in gut-associated lymphoid 
tissue and increase in IL-10 production were observed [173].
Besides, it was also demonstrated in a DSS-induced colitis mouse model that the 
oral administration of L. lactis NZ900 strain harboring the NICE system express-
ing either the anti-inflammatory cytokine IL-10, TGF-β1, secretory leukocyte 
protease inhibitor (SLPI), or elafin was able to ameliorate some clinical parameters 
in inflamed mice. Even though it was possible to observe the reduction of weight 
loss and diarrhea, microscopic colonic damage scores, colon thickness, and myelo-
peroxidase (MPO) activity, the authors reported that treatments with recombinant 
L. lactis strain delivering either SLPI or elafin were more efficient to reduce signs 
of colitis than treatments with anti-inflammatory cytokines. Altogether these 
recombinant strains display anti-inflammatory effects in inflamed mice [174].
Approaches using the invasive L. lactis MG1363 FnBPA+, by expressing the FnBpA 
protein at their surface and carrying the pValac eukaryotic expression vector coding 
either the IL-10 cytokine [rL. lactis FnPBA+ (pValac:il-10)] or the IL-4 cytokine [rL. 
lactis FnPBA+ (pValac:il-4)] in DSS or trinitrobenzenesulfonic acid (TNBS)-induced 
acute model of colitis, respectively, were also investigated. The administration of L. 
lactis FnPBA+ (pValac:il-10) recombinant strain was capable to reduce the intestinal 
inflammation by increasing IL-10 levels and sIgA production, accompanied by 
decreasing IL-6, as well as the restoration of intestinal architecture of mice colon 
[153]. Besides, the engineered L. lactis FnPBA+ (pValac:il-4) was able to slump the 
level of pro-inflammatory cytokine (IL-12, IL-6) and myeloperoxidase activity and 
increase levels of IL-4 and IL-10, consequently decreasing the colitis harshness [153].
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Microorganism Gene Expression 
System
Inflamation 
Condition
Anti-
Inflamatory 
Properties
References
L. lactis MG1363 Mouse IL-10 SICE Mouse model of 
DNBS-induced 
colitis
Restoration 
of intestinal 
architecture; IgA 
production and 
IL-6 reduction; 
Reduced tissue 
damage
[134]
L. lactis MG1363 Mouse IL-10 and 
IL-4
pValac 
vector
Mouse model 
of DSS/TNBS-
induced colitis
Decreased IL-6, 
IL-12 and MPO 
activity
Reduced tissue 
damage
[152-153]
L. lactis NZ9000 Mouse TGF-β1; 
IL-10
and leukocyte 
protease inhibitor
Human Elafin
NICE Mouse model 
of DSS-induced 
colitis
Reduced tissue 
damage
Decreased pro-
inflammatory 
cytokines
[174]
L. lactis NCDO 
2118
Human 
15-lipoxygenase-1
XIES Mouse model 
of DSS-induced 
colitis
Reduced tissue 
damage
[175]
L. lactis NCDO 
2118
M. leprae Hsp65 
protein
XIES Mouse model 
of DSS-induced 
colitis
Restoration 
of intestinal 
architecture
CD4+Foxp3+ 
and CD4+LAP+ 
regulatory T cells 
production
[176]
B. bifidum BS42 Mouse IL-10 BEST Mouse model of 
DNBS-induced 
colitis
Reduced tissue 
damage
[177]
L. casei BL23 Superoxide 
dismutase A from 
L.lactis MG1363
Catalase from 
L.plantarum 
ATCC
pLEM415 
vector
Mouse model of 
TNBS-induced 
Crohn´s disease
Reduced tissue 
damage
Reduced 
microbial 
translocation
Increase IL-10/
INF-γ reduction
[180]
S. thermophilus 
CLR807
Superoxide 
dismutase A from 
L.lactis MG1363
Catalase from 
L.plantarum 
ATCC
pIL253 
vector
Mouse model of 
TNBS-induced 
colitis
Reduced tissue 
damage
Reduced 
microbial 
translocation
IL-17 reduction
[181]
L.lactis AG013 Human Trefoil 
Factor 1 (Htff-1)
ThyA native 
promoter of 
L.lactis
Hamster model of 
radiation-induced 
oral mucositis
Reduced clicnical 
scores of oral 
mucositis
[186]
L. lactis NZ9000 Human 
pancreatitis 
associated protein 
(Reg3A)
NICE Mouse model of 
5-FU-induced 
intestinal 
mucositis
Microbiota 
Regulation
Villus 
architecture 
preservation
Increased Paneth 
cells activity
[185, 187]
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The human 15-lipoxygenase-1-producing L. lactis NCDO2118 harboring the 
xylose-inducible expression system (pXylt:CYT:15-LOX-1) was also effective in 
attenuating the symptoms of DSS-induced colitis in a murine model [175]. Its oral 
administration improved the body weight, decreased pro-inflammatory cytokines 
(IFN-γ and IL-4) while increasing the anti-inflammatory cytokine IL-10, and, 
consequently, ameliorated the macroscopic damage scores associated with the 
inflammation.
The oral pretreatment with genetically modified L. lactis NCDO2118 
able to secrete HSP65 protein from Mycobacterium leprae, using XIES system 
(pXylt:SEC:hsp65), prevented DSS-induced colitis in C57BL/6 mice [176]. This 
protection was associated with reduced pro-inflammatory cytokines, such as IFN-γ, 
IL-6, and TNF-α; it also increased IL-10 production in colonic tissue and expansion 
of CD4+FoxP3+ and CD4+ latency-associated peptide (LAP+) regulatory T cells in 
the spleen and mesenteric lymph nodes. Besides, the authors showed that this effect 
was dependent on IL-10 and toll-like receptor 2 (TLR-2) [176].
Although L. lactis represents an excellent candidate for a live mucosal vec-
tor delivery system, other bacteria have also been explored as promising live 
vehicles for molecule expression with therapeutic properties, such as Lactobacillus, 
Bifidobacterium, and Streptococcus. In this context, Mauras et al. [177] using the 
new Bifidobacteria Expression SysTem (BEST) allowing the production of IL-10 in 
Bifidobacterium bifidum BS42(pBESTExp4:il-10 and pBESTBL1181:il-10) demon-
strated that the use of these recombinant strains in a DNBS-induced colitis model 
showed its ability to decrease local inflammation and confirmed therefore its 
potential for delivery of therapeutic molecules in the colon.
It is well known that IBD is associated with oxidative stress by the increase 
in concentration of reactive oxygen species in the GIT and impaired antioxidant 
defenses [178, 179]. In this context, it has been shown that some probiotic LAB 
strains may play a protective role in IBD by expressing antioxidant enzymes such as 
superoxide dismutase (SOD) and catalase (CAT) [180, 181].
LeBlanc et al. and Del Carmen et al. [180, 181] showed, respectively, that L. 
casei BL23 and S. thermophilus CRL807 transformed with two different plasmids 
(pLEM415:mnkat; pLEM415:sodA) (pIL253:sodA and pIL253:mnkat) harboring 
Microorganism Gene Expression 
System
Inflamation 
Condition
Anti-
Inflamatory 
Properties
References
L.lactis 
NCDO2118
M. leprae Hsp65 
protein
XIES Mice model of 
experimental 
encephalomyelitis
Increased 
CD4+Foxp3+ 
regulatory T cells
Reduced 
encephalytogenic 
CD4+ T cells
[184]
L.lactis MG1363 Mouse IL-17 SICE Mice model HPV-
induced cancer
Reduced tumor 
size
Induced IL-6 and 
IL-17 secretion
[182]
L.lactis NZ9000 M. leprae Hsp65 
protein and 
peptide derived 
of human Hsp60 
protein
NICE Mice model of 
diabetes type 1
Reduction of 
insulitis
Inhibition of T 
cell proliferation
[183]
Table 1. 
Protein with anti-inflammatory properties produced in different strains of bacteria.
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the genes encoding catalase (CAT) or superoxide dismutase (SOD) antioxidant 
enzymes exhibited anti-inflammatory activities in a mouse model of Crohn’s 
and colitis disease induced by trinitrobenzenesulfonic acid (TNBS). The authors 
observed a reduction in weight loss, fewer liver microbial translocation, lower mac-
roscopic and microscopic damage scores, and modulation of the IFN-γ/IL-10 [180] 
and IL-10/IL-17 [181] cytokine production in the large intestines of mice treated 
with either CAT- or SOD-producing lactobacilli/streptococci.
The stress-inducible controlled expression (SICE) system represented by 
L. lactis MG1363 strain harboring the pLB333 plasmid was developed to avoid 
the external induction of culture before the host administration [134]. Several 
interesting molecules were cloned in this system such as IL-10 [134] and IL-17 
[182], and the effect of L. lactis secreting them was evaluated in mice models. L. 
lactis (pSICE:il-10) was tested in a DNBS-induced colitis mice model, resulting in 
a significant reduction in colitis parameters with improvement in weight loss and 
a decrease in macroscopic scores [134]. The intranasal administration with L. 
lactis secreting IL-17A (pSICE:il-17), in a mice model of human papilloma virus 
(HPV)-induced cancer, was able to reduce tumor size and induce IL-6 and IL-17 
secretion in reactivated splenocytes from mice challenged with the tumoral cell 
line [182]. Both works confirmed the potential use of L. lactis harboring the SICE 
system to deliver interesting molecules either to colitis or colon cancer patients 
[134, 182].
Although many studies have focused on the use of recombinant bacteria for the 
treatment of IBDs, as was previously discussed, the use of recombinant probiotic 
strains expressing/delivering therapeutic molecules has been explored for treatment 
or prevention of other diseases such as mucositis, cancer, obesity, multiple sclerosis, 
and diabetes [182–185].
An in vivo study reported by Caluwaerts et al. [186] showed that recombinant 
L. lactis AG013 secreting human trefoil factor 1(hTFF-1) was able to reduce the 
severity and course of radiation-induced oral mucositis. Carvalho et al. [187] also 
demonstrated that a recombinant strain of L. lactis NZ9000 using the inducible 
NICE system to express the human pancreatitis-associated protein (PAP) was able 
to prevent 5-FU-induced intestinal mucositis in a murine model. It was observed 
that this protein preserved villous architecture, increased Paneth cell activity [187], 
and suppressed the growth of Enterobacteriaceae during inflammation [185].
It also has been shown that oral administration of a recombinant L. lactis 
NCDO2118 strain (pXylT:SEC:hsp65) prevented the development of experimental 
autoimmune encephalomyelitis (EAE) in C57BL/6 mice [184]. Mice fed daily with 
this recombinant strain increased the number of natural and inducible CD4+FoxP3+ 
and CD4+ latency-associated peptide (LAP+) regulatory T cells in the spleen, 
inguinal and mesenteric lymph nodes, as well as in the spinal cord. In addition, a 
reduction in the recruitment of encephalitogenic CD4+ T cells to the spinal cord 
was observed, which decreased IgG response against HSP65 and induced an anti-
inflammatory cytokine profile (IL-17 reduction and IL-10 increase) during EAE 
development.
The oral administration of recombinant L. lactis expressing HSP65 and tan-
demly repeated P277 (pCYT:HSP65-6P277) was also analyzed in a model of type 
1 diabetes mellitus (DM1) [183]. The authors observed that oral administration 
of recombinant L. Lactis resulted in the prevention of hyperglycemia, improved 
glucose tolerance and reduced insulitis, and induced HSP65- and P277-specific 
T-cell immunotolerance, as well as antigen-specific proliferation of splenocytes, 
demonstrating to be an effective therapeutic approach in preventing DM1 [183].
Another study using the E. coli Nissle 1917 strain engineered to secrete 
N-acylphosphatidylethanolamines (NAPEs) (pDEST-At1g78690 expression 
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plasmid) demonstrated that this strain was able to reduce the obesity of mice fed 
with a high-fat diet when added to drinking water. N-acyl phosphatidylethanol-
amines are precursors to the N-acylethanolamine (NAE) family of lipids, which 
are synthesized in the small intestine in response to feeding and reducing food 
intake and obesity. Mice that received modified bacteria had dramatically lower 
food intake, adiposity, insulin resistance, and hepatosteatosis than mice receiving 
standard water or control bacteria [188]. In addition, it was observed that changes 
on intestinal microbiota significantly decreased the abundance of Firmicutes and 
increased the abundance of Proteobacteria. Thus, these results provide evidence 
of the potential efficacy of this approach to inhibit the development of metabolic 
disorders and related diseases.
13. Conclusion
Currently the association between disease progression, especially chronic 
inflammatory diseases, and intestinal dysbiosis has been more frequently observed. 
As a clinical strategy, the use of probiotic bacteria, which naturally benefit the host, 
has been increasingly used on the treatment of diseases related to the GIT. In view 
of the good results obtained with this approach, researchers have sought through 
bacterial genetic modification to increase the beneficial potential of probiotics, 
either through their use for heterologous protein production or as a vehicle for 
vaccinal plasmid delivery, by developing recombinant bacterial strains and by 
testing their action in different disease models. And while there are still a number 
of questions that need to be answered about the use of genetically modified organ-
isms for health care, especially in human, the use of these strains has proven to be 
a potentially effective therapeutic alternative, so much so that clinical trials using 
recombinant lineages have already been authorized and conducted in humans.
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